{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:19:22Z","timestamp":1778876362503,"version":"3.51.4"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,11,7]],"date-time":"2017-11-07T00:00:00Z","timestamp":1510012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["TRR60"],"award-info":[{"award-number":["TRR60"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8146113009"],"award-info":[{"award-number":["8146113009"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chinese National Key Technology R&D Program","award":["2015BAI09B06"],"award-info":[{"award-number":["2015BAI09B06"]}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["HHSN272201000039I\/HHSN27200001\/A19"],"award-info":[{"award-number":["HHSN272201000039I\/HHSN27200001\/A19"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.antiviral.2017.10.022","type":"journal-article","created":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T01:31:11Z","timestamp":1510104671000},"page":"26-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Activity of nucleic acid polymers in rodent models of HBV infection"],"prefix":"10.1016","volume":"149","author":[{"given":"Katrin","family":"Sch\u00f6neweis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Motter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pia L.","family":"Roppert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengji","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baoju","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo","family":"Roehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dieter","family":"Glebe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongliang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Morrey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3293-6738","authenticated-orcid":false,"given":"Michael","family":"Roggendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Vaillant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2017.10.022_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156667","article-title":"Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive bangladeshi patients with HBeAg+ chronic hepatitis B infection","volume":"11","author":"Al-Mahtab","year":"2016","journal-title":"PLOS ONE"},{"key":"10.1016\/j.antiviral.2017.10.022_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-1253(17)30288-1","article-title":"Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial","author":"Bazinet","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2017.10.022_bib3","doi-asserted-by":"crossref","first-page":"S256","DOI":"10.1016\/S0168-8278(17)30821-8","article-title":"Update on safety and efficacy in the REP 401 protocol: REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated Interferon alpha-2a in treatment na\u00efve caucasian patients with chronic HBeAg negative HBV infection","volume":"66","author":"Bazinet","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2017.10.022_bib4","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jhep.2015.11.032","article-title":"In vivo reduction of hepatitis B virus antigenemia and virema by antisense oligonucleotides","volume":"64","author":"Billioud","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2017.10.022_bib5","doi-asserted-by":"crossref","first-page":"S257","DOI":"10.1016\/S0168-8278(17)30823-1","article-title":"Post-entry antiviral effects of nucleic acid polymers against hepatitis B virus infection in vitro. J","volume":"66","author":"Blanchet","year":"2017","journal-title":"Hepatol"},{"key":"10.1016\/j.antiviral.2017.10.022_bib6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1099\/0022-1317-27-2-117","article-title":"Host components in hepatitis B antigen","volume":"27","author":"Burrell","year":"1975","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2017.10.022_bib7","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/S0022-2275(20)37904-9","article-title":"Distribution and characterization of the serum lipoproteins and apoproteins in the mouse, Mus musculus","volume":"24","author":"Camus","year":"1983","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.antiviral.2017.10.022_bib8","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/1743-422X-6-214","article-title":"Amphipathic DNA polymers exhibit antiviral activity against systemic murine Cytomegalovirus infection","volume":"6","author":"Cardin","year":"2009","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2017.10.022_bib9","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.1128\/JVI.00561-08","article-title":"Properties of subviral particles of hepatitis B virus","volume":"82","author":"Chai","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2017.10.022_bib10","first-page":"261","article-title":"Duck hepatitis B virus model in the study of hepatitis B virus","volume":"96","author":"Cova","year":"2004","journal-title":"Methods Mol. Med."},{"key":"10.1016\/j.antiviral.2017.10.022_bib11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.bpg.2017.04.014","article-title":"Animal models of HBV infection","volume":"31","author":"Dandri","year":"2017","journal-title":"Best. Pract. Res. Clin. Gastroenterol."},{"key":"10.1016\/j.antiviral.2017.10.022_bib12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/095632020701800405","article-title":"Development of a novel mouse model to evaluate drug candidates against hepatitis B virus","volume":"18","author":"Feitelson","year":"2007","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2017.10.022_bib13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.virol.2006.09.006","article-title":"Enzymatic treatment of duck hepatitis B virus: topology of the surface proteins for virions and non-infectious subviral particles","volume":"359","author":"Franke","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2017.10.022_bib14","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1128\/AAC.47.8.2624-2635.2003","article-title":"Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection","volume":"47","author":"Foster","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2017.10.022_bib15","doi-asserted-by":"crossref","first-page":"7770","DOI":"10.1016\/S0021-9258(18)34448-X","article-title":"Structure of hepatitis B surface antigen","volume":"257","author":"Gavilanes","year":"1982","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2017.10.022_bib16","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.antiviral.2017.10.022_bib17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40262-014-0224-4","article-title":"Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (Kynamro\u00ae): a second-generation antisense oligonucleotide inhibitor of apolipoprotein B","volume":"54","author":"Geary","year":"2015","journal-title":"Clin. Pharmocokinet"},{"key":"10.1016\/j.antiviral.2017.10.022_bib18","first-page":"57","article-title":"Quantitative assay of hepatitis B surface antigen in serum or plasma using laurel electrophoresis","volume":"95","author":"Gerlich","year":"2004","journal-title":"Meth.Mol. Med."},{"key":"10.1016\/j.antiviral.2017.10.022_bib19","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/CIRCRESAHA.111.300367","article-title":"Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans","volume":"112","author":"Graham","year":"2013","journal-title":"Circ. Res."},{"key":"10.1016\/j.antiviral.2017.10.022_bib20","doi-asserted-by":"crossref","first-page":"6158","DOI":"10.1128\/jvi.69.10.6158-6169.1995","article-title":"High-level hepatitis B virus replication in transgenic mice","volume":"69","author":"Guidotti","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2017.10.022_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179697","article-title":"Inhibition of hepatitis viral entry by nucleic acid polymers in HepaRG cells and primary human hepatocytes","volume":"12","author":"Guillot","year":"2017","journal-title":"PLOS ONE"},{"key":"10.1016\/j.antiviral.2017.10.022_bib22","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0305-0491(98)10038-X","article-title":"Phospholipid and cholesteryl ester transfer activity in plasma from 14 vertebrate species. Relation to atherogenesis susceptibility","volume":"120","author":"Guyard-Dangremont","year":"1998","journal-title":"Comp. Biochem. Physiol. Biochem. Mol. Biol."},{"key":"10.1016\/j.antiviral.2017.10.022_bib23","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jhep.2015.03.020","article-title":"Characterization of novel entecavir resistance mutations","volume":"63","author":"Hayashi","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2017.10.022_bib24","article-title":"Mouse models of hepatitis B virus pathogenesis","volume":"5","author":"Innacone","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.antiviral.2017.10.022_bib25","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","article-title":"Treatment of HCV infection by targeting microRNA","volume":"368","author":"Janssen","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2017.10.022_bib26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0166-3542(01)00223-6","article-title":"Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus","volume":"55","author":"Julander","year":"2002","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.10.022_bib27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0166-3542(03)00109-8","article-title":"Characterization of antiviral activity of entecavir in transgenic mice expressing hepatitis B virus","volume":"59","author":"Julander","year":"2003","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.10.022_bib28","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/0005-2760(75)90077-6","article-title":"Properties of rooster serum high density lipoproteins","volume":"409","author":"Kruski","year":"1975","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.antiviral.2017.10.022_bib29","doi-asserted-by":"crossref","first-page":"12242","DOI":"10.1128\/JVI.79.19.12242-12252.2005","article-title":"Covalently closed circular DNA is the predominant form of duck hepatitis B virus DNA that persists following transient infection","volume":"79","author":"Le Mire","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2017.10.022_bib30","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1089\/oli.1.2000.10.435","article-title":"Comparison of the pharmacokinetics of subcutaneous and intravenous administration of a phosphorothioate oligodeoxynucleotide in cynomolgus monkeys","volume":"10","author":"Leeds","year":"2000","journal-title":"Antisense Nucleic Acid. Drug. Dev."},{"key":"10.1016\/j.antiviral.2017.10.022_bib31","series-title":"Antisense Drug Technology: Principles, Strategies, and Applications","first-page":"183","article-title":"Basic principles of the pharmacokinetics of antisense oligonucleotide drugs","author":"Levin","year":"2007"},{"key":"10.1016\/j.antiviral.2017.10.022_bib32","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0042-6822(03)00403-3","article-title":"Cholesterol requirement of hepatitis B surface antigen (HBsAg) secretion","volume":"314","author":"Lin","year":"2002","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2017.10.022_bib33","series-title":"Frontiers in Viral Hepatitis","first-page":"197","article-title":"A transgenic mouse lineage useful for testing antivirals targeting hepatitis B virus","author":"Marion","year":"2003"},{"key":"10.1016\/j.antiviral.2017.10.022_bib34","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1136\/gutjnl-2014-308041","article-title":"TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T-cells and exerts an antivital effect in HBV-persistent mice","volume":"64","author":"Martin","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2017.10.022_bib35","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1053\/j.gastro.2009.04.048","article-title":"Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry","volume":"137","author":"Matsumura","year":"2009","journal-title":"Gastroenterol"},{"key":"10.1016\/j.antiviral.2017.10.022_bib36","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1128\/JVI.02086-13","article-title":"Novel woodchuck hepatitis virus (WHV) transfene mouse models show sex-dependent WHV replicative activity and development of spontaneous immune responses to WHV proteins","volume":"288","author":"Meng","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2017.10.022_bib37","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.antiviral.2015.11.001","article-title":"Combination therapy including CpG oligodeoxynucleotides and entecavir induces early viral response and enhanced inhibition of viral replication in a woodchuck model of chronic hepadnaviral infection","volume":"125","author":"Meng","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.10.022_bib38","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1128\/AAC.00654-08","article-title":"Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection","volume":"52","author":"Menne","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2017.10.022_bib39","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jhep.2014.12.026","article-title":"Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B","volume":"62","author":"Menne","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2017.10.022_bib40","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jinf.2015.09.038","article-title":"Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones","volume":"72","author":"Murakami","year":"2016","journal-title":"J. Infect."},{"key":"10.1016\/j.antiviral.2017.10.022_bib41","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1073\/pnas.71.7.2663","article-title":"Hepatitis B antigen: antigen sites related to human serum proteins revealed by affinity chromatography","volume":"71","author":"Neurath","year":"1974","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2017.10.022_bib42","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1128\/AAC.42.12.3130","article-title":"Inhibition of duck hepatitis B virus replication by 9-(2-phosphonylmethoxyethyl) adenine, an acyclic phosphonate nucleoside analogue","volume":"42","author":"Nicoll","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2017.10.022_bib43","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1128\/AAC.01005-13","article-title":"Nucleic acid polymers prevent the establishment of duck hepatitis virus infection in vivo","volume":"57","author":"Noordeen","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2017.10.022_bib44","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1128\/AAC.01003-13","article-title":"Nucleic acid polymers inhibit duck hepatitis B virus infection in vitro","volume":"57","author":"Noordeen","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2017.10.022_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140909","article-title":"Therapeutic antiviral effect of the nucleic acid polymer REP 2055 against persistent duck hepatitis B virus infection","volume":"10","author":"Noordeen","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.antiviral.2017.10.022_bib46","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2174\/187231210791698456","article-title":"Morphologic characterization of PhoenixBio (uPA+\/+\/SCID) humanized liver chimeric mouse model","volume":"4","author":"Peterson","year":"2010","journal-title":"Drug Metab. Lett."},{"key":"10.1016\/j.antiviral.2017.10.022_bib47","doi-asserted-by":"crossref","first-page":"7651","DOI":"10.1021\/acs.jmedchem.6b00879","article-title":"Design and synthesis of orally bioavailable 4-methyl heteroaryldihydropyrimidine based hepatitis B virus (HBV) capsid inhibitors","volume":"59","author":"Qiu","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2017.10.022_bib48","doi-asserted-by":"crossref","first-page":"S385","DOI":"10.1016\/S0168-8278(16)00590-0","article-title":"Achievement of surface antigen clearance in the liver by combination therapy with REP 2139-Ca and nucleoside analogs against chronic hepatitis B","volume":"64","author":"Quinet","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2017.10.022_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2017.04.019","article-title":"Nucleic acid polymers with accelerated plasma and tissue clearance for chronic hepatitis B therapy","volume":"8","author":"Roehl","year":"2017","journal-title":"Mol. Ther. Nuc. Acids"},{"key":"10.1016\/j.antiviral.2017.10.022_bib50","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/oxfordjournals.jbchem.a022639","article-title":"Membrane structure of the hepatitis B virus surface antigen particle","volume":"127","author":"Satoh","year":"2000","journal-title":"J. Biochem."},{"key":"10.1016\/j.antiviral.2017.10.022_bib51","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.1128\/AAC.01483-12","article-title":"Evaluation of single and combination therapies with tenofovir disoproxil fumarate and emtricitabine in vitro and in a robust mouse model supporting high levels of hepatitis B virus","volume":"56","author":"Schinazi","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2017.10.022_bib52","series-title":"Presented at the Australian Center for HIV and Hepatitis Virology Research Workshop. June 4th, 2012, Adelaide, Australia","article-title":"To study the ability of tenofovir and emtricitabine in monotherapy and combination therapy to treat chronic duck hepatitis B virus infection in vivo","author":"Scougall","year":"2012"},{"key":"10.1016\/j.antiviral.2017.10.022_bib53","doi-asserted-by":"crossref","first-page":"G844","DOI":"10.1152\/ajpgi.00200.2010","article-title":"Lipoprotein profiles in SCID\/uPA mice transplanted with human hepatocytes become human-like and correlate with HCV infection success","volume":"299","author":"Steenbergen","year":"2010","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.antiviral.2017.10.022_bib54","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1073\/pnas.75.9.4533","article-title":"A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchucks","volume":"75","author":"Summers","year":"1978","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2017.10.022_bib55","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/hep.20892","article-title":"Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus","volume":"42","author":"Tsuge","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2017.10.022_bib56","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/hep.22057","article-title":"Susceptibility of chimeric mice with livers repopulated by serially subcultured human hepatocytes to hepatitis B virus","volume":"47","author":"Utoh","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2017.10.022_bib57","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.antiviral.2016.07.004","article-title":"Nucleic acid polymers: broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection","volume":"113","author":"Vaillant","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.10.022_bib58","series-title":"Antisense Drug Technology: Principles, Strategies, and Applications","first-page":"305","article-title":"Pharmacokinetic\/pharmacodynamic properties of phosphorothioate 2'-O-(2-Methoxyethyl)-modified antisense oligonucleotides in animals and man","author":"Yu","year":"2007"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421730596X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421730596X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:26:41Z","timestamp":1759062401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016635421730596X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":58,"alternative-id":["S016635421730596X"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.10.022","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity of nucleic acid polymers in rodent models of HBV infection","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.10.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}